

## **Report from Annual General Meeting in Affibody Medical AB (publ)**

**June 30, 2021**

**Affibody Medical AB (publ) today held its Annual General Meeting. The annual general meeting was held through advance voting (postal voting) in accordance with temporary legislation. The following resolutions were adopted.**

### *Adoption of the income statement and the balance sheet; allocation of result and discharge from liability*

The general meeting adopted the income statement and balance sheet for the company in accordance with submitted accounting documents. The general meeting further resolved to allocate the company's result in accordance with the board's proposal. The annual general meeting resolved to discharge the board members and the managing director from liability for the financial year 2020.

### *Election of board members and auditor and resolutions regarding fees*

The current board consisting of Robert Burns, Gillian M. Cannon, Jonathan Knowles, Jakob Lindberg, José F. Suarez and Mathias Uhlén was re-elected. Robert Burns was re-elected as chairman. Ernst & Young AB was re-elected as the company's auditor. Anna Svanberg will remain as lead auditor. The board fees, as well as the fees to the auditor, remain unchanged.

### *Nomination committee instructions*

The general meeting resolved on instructions for a nomination committee to be established in preparation for the annual general meeting in 2022.

### *Adoption of new Articles of Association*

The general meeting adopted new Articles of Association in accordance with the proposal set out in the notice to the meeting.

### *Issue of convertibles*

The general resolved to issue convertibles to Duba AB in the amount of up to SEK 101.4m.

### *Establishment of employee stock option program*

The general meeting established a 2021/2028 employee stock option program consisting of up to 1 500 000 options. The shareholders resolved to accept the participation of the board in the program.

### *Authorization for issues of shares, convertibles and warrants*

The general meeting authorized the Board of Directors to, on one or several occasions during the period up to the next annual general meeting, increase the company's share capital through issues of new shares, convertible instruments and/or warrants, with or without deviating from the shareholder's preferential rights, and with or without provisions on payment by non-cash consideration and/or by way of set-off or other provisions.